Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 17,165,367 ordinary shares.

 

Following the above purchase, the Company will hold 235,299,750 ordinary shares in treasury and have 4,080,085,660 ordinary shares in issue (excluding Treasury shares).

 

The total number of voting rights in the Company is 4,080,085,660. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.77 per cent.

 

The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.

 

 

 

Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)

 

Date of purchases:     25 July 2025

 

Investment firm:        Merrill Lynch International

 

 

 

Venue	Number of ordinary shares purchased	Highest price paid (per ordinary share) (GBp)	Lowest price paid (per ordinary share) (GBp)	Volume weighted average price paid (per ordinary share) (GBp)
London Stock Exchange (XLON)	488,010	1,398.00p	1,387.00p	1,392.64p
CBOE (CHIX)	0	-	-	-
CBOE (BATE)	0	-	-	-